For patients with ALK-positive non-small-cell lung cancer (NSCLC) the standard first-line therapy is crizotinib. Resistance to first-line ALK inhibitors is common — inevitably, patients relapse, and can develop metastases in the central nervous system (CNS). The second-generation ALK inhibitor alectinib is able to penetrate the

中文翻译：

---

靶向疗法：定义非小细胞肺癌中的同类最佳药物

对于ALK阳性的非小细胞肺癌（NSCLC）患者，标准的一线疗法为克唑替尼。对一线ALK抑制剂的耐药性很常见-不可避免地，患者会复发，并且可能在中枢神经系统（CNS）中发生转移。第二代ALK抑制剂alectinib能够穿透